Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice.
Salam Hussain, Chris Gale, Shanthi Sarma, Jeremy L Smith, Adam Bayes, Colleen Loo
Australian & New Zealand Journal of Psychiatry April 28, 2025 DOI: 10.1177/00048674251333577 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical practice guideline Peer reviewed |
|---|---|
| Intervention | Ketamine |
| Topics | Depression Ketamine Esketamine |
| Keywords | Professional practice Psychiatric disorders Mental health treatment Ketamine therapy Clinical guidelines Depression management Psychiatric medicine |
| Citations | 10 |
| Key points | The guidelines provide consensus-based recommendations for the use of ketamine in psychiatric practice, aiming to balance evidence-based practice with the evolving evidence for ketamine. |
Abstract
Professional practice guidelines for the use of ketamine in psychiatric practice have been developed by the Royal Australian and New Zealand College of Psychiatrists to provide guidance on the use of ketamine in clinical practice in Australia and Aotearoa New Zealand, based on scientific evidence and supplemented by expert clinical consensus. Articles and information were sourced from existing guidelines and published literature. The findings were then formulated into consensus-based recommendations and guidance by the authors. The guidelines were subjected to rigorous successive consultation within the Royal Australian and New Zealand College of Psychiatrists, involving the Section of Electroconvulsive Therapy and Neurostimulation Committee, its broader membership and expert committees. The guidelines are intended for psychiatrists and clinicians engaged in the use of ketamine therapy to facilitate best practice to optimise outcomes for patients. They strive to find the appropriate balance between promoting best evidence-based practice and acknowledging that evidence for ketamine use is continually evolving.
Citations in the library
Cited by 7
- Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis Current Oncology June 30, 2025
- Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy Australian & New Zealand Journal of Psychiatry December 11, 2025
- Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia Australian & New Zealand Journal of Psychiatry May 26, 2026
- Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). Journal of Affective Disorders May 16, 2026
- Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study The British Journal of Psychiatry July 6, 2026
and 2 more in the library
Cites 56
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- Mechanisms of Ketamine Action as an Antidepressant Molecular Psychiatry March 13, 2018
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
and 51 more in the library